Short-course HIPEC in Advanced Epithelial Ovarian Cancer
Status:
Completed
Trial end date:
2021-02-23
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, single-arm, feasibility phase 2 trial on safety and
efficacy of short-course regimen of intra-operative Hyperthermic Intraperitoneal Chemotherapy
(HIPEC) at the time of fast-track interval debulking surgery (IDS) following neoadjuvant
chemotherapy (NACT) for high tumor burden epithelial ovarian cancer (EOC).
Phase:
Phase 2
Details
Lead Sponsor:
Professor Fernando Figueira Integral Medicine Institute
Collaborators:
AC Camargo Cancer Center AC Camargo Cancer Center (São Paulo/SP) Hospital de Base do Distrito Federal (Brasilia/DF) Hospital de Cancer de Barretos - Fundacao Pio XII (Barretos/SP) Hospital de Câncer de Pernambuco Hospital de Câncer de Pernambuco (Recife/PE) Hospital Sao Jose (Criciuma/SC) Instituto Brasileiro de Controle do Câncer (São Paulo/SP)